Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

XPG is Predictive Gene of Clinical Outcome in Advanced Non-small-cell Lung Cancer with Platinum Drug Therapy

  • Zhang, Tian (Department of Radiotherapy, Beijing Chaoyang Hospital, Capital Medical University) ;
  • Sun, Jing (Department of Dermatology, The China-Japan Union Hospital of Jilin University) ;
  • Lv, Min (Department of Cardiac Surgery, The China-Japan Union Hospital of Jilin University) ;
  • Zhang, Lin (Department of Orthopedics, Beijing Shijitan Hospital, Capital Medical University) ;
  • Wang, Xia (The Fourth Department of Tuberculosis, the First Affiliated Hospital, Xinxiang Medical College) ;
  • Ren, Ji-Chen (Department of Oncology, Tumor Hospital of Jilin Provice) ;
  • Wang, Bin (Department of Oncological Surgery, Tumor Hospital of Jilin Provice)
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Polymorphisms in XPG are considered to contribute to the clinical outcome of patients receiving platinum drug chemotherapy. We aimed to investigate the role of five potential SNPs of XPG gene on the response to platinum-based chemotherapy in advanced Chinese NSCLC patients. A total of 451 patients with newly diagnosed and histopathologically confirmed primary NSCLC were consecutively collected. XPG rs2296147, rs4150261, rs17655, rs1047768 and rs2094258 were genotyped by the Taqman real-time polymerase chain reaction (PCR). In our study, we found patients carrying rs1057768 TT genotype had a significantly lower treatment response when compared with the CC genotype (OR=0.38, 95% CI=0.18-0.78). Patients carrying rs1047768 TT genotype showed a significantly short median PFS (11.2 months) and OS (13.6 months) than CC genotype, and the hazard ratios (HR) for PFS and OS were 2.06 (1.01-4.50) and 2.29 (1.21-2.49), respectively. Moreover, we found a significant decreased risk of death from NSCLC among patients carrying the rs2296147 TT genotype when compared with the CC genotype, the HR (95% CI) for OS being 0.50 (0.27-0.95). In conclusion, our study found that polymorphisms in rs1047768 C/T and rs2296147 C/T are associated with response to platinum-based chemotherapy in advanced NSCLC, and XPG polymorphisms could be predictive of prognosis.

Keywords

References

  1. Bartolucci R, Wei J, Sanchez JJ, et al (2009). XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer, 10, 47-52. https://doi.org/10.3816/CLC.2009.n.007
  2. Chang JS, Wrensch MR, Hansen HM, et al (2008) Nucleotide excision repair genes and risk of lung cancer among San Francisco Bay Area Latinos and African Americans. Int J Cancer, 123, 2095-104. https://doi.org/10.1002/ijc.23801
  3. Chen J, Xie F, Chen K, et al (2009). ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer. Cancer Biol Ther, 8, 1424-30. https://doi.org/10.4161/cbt.8.14.8889
  4. Clarkson SG (2003). The XPG story. Biochimie, 85, 1113-21. https://doi.org/10.1016/j.biochi.2003.10.014
  5. Cordonnier AM, Fuchs RP (1999). Replication of damaged DNA: molecular defect in xeroderma pigmentosum variant cells. Mutat Res, 435, 111-9. https://doi.org/10.1016/S0921-8777(99)00047-6
  6. Fleming ND, Agadjanian H, Nassanian H, et al (2012). Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Cancer, 118, 689-97. https://doi.org/10.1002/cncr.26329
  7. Friedberg EC, Bond JP, Burns DK, et al (2000). Defective nucleotide excision repair in XPC mutant mice and its association with cancer predisposition. Mutat Res, 459, 99-108. https://doi.org/10.1016/S0921-8777(99)00068-3
  8. Friedberg EC (2003). DNA damage and repair. Nature, 421, 436-40. https://doi.org/10.1038/nature01408
  9. Jemal A, Thomas A, Murray T, et al (2002). Cancer statistics, 2002. CA Cancer J Clin, 52, 23-47. https://doi.org/10.3322/canjclin.52.1.23
  10. He C, Duan Z, Li P, Xu Q, et al (2013). Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer. Anticancer Drugs, 24, 300-5. https://doi.org/10.1097/CAD.0b013e32835bd6ce
  11. He J, Qiu LX, Wang MY, et al (2012). Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet, 131, 1235-44. https://doi.org/10.1007/s00439-012-1152-8
  12. Liu D, Wu HZ, Zhang YN, et al (2012). DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy. Mol Carcinog, 51, E83-93. https://doi.org/10.1002/mc.21862
  13. International Agency for Research on Cancer (2008). Lung cancer incidence, Mortality and Prevalence Worldwide in 2008. http://globocan.iarc.fr/factsheet.asp.
  14. Molina JR, Yang P, Cassivi SD, et al (2008). Non-small cell lung cancer:epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 83, 584-94. https://doi.org/10.1016/S0025-6196(11)60735-0
  15. Mudgett JS, MacInnes MA (1990). Isolation of the functional human excision repair gene ERCC5 by intercosmid recombination. Genomics, 8, 623-33. https://doi.org/10.1016/0888-7543(90)90248-S
  16. Nouspikel T, Lalle P, Leadon SA, Cooper PK, Clarkson SG (1997). A common mutational pattern in Cockayne syndrome patients from xeroderma pigmentosum group G: implications for a second XPG function. Proc Natl Acad Sci U S A, 94, 3116-21. https://doi.org/10.1073/pnas.94.7.3116
  17. Sakano S, Hinoda Y, Sasaki M, et al (2010). Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. Pharmacogenomics, 11, 1377-87. https://doi.org/10.2217/pgs.10.106
  18. Sun X, Li F, Sun N, et al (2009). Polymorphisms in XRCC1 and XPG and response to platinumbased chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer, 65, 230-6. https://doi.org/10.1016/j.lungcan.2008.11.014
  19. Tahara E, Yasui W, Ito H, et al (2009). Recent progress in carcinogenesis, progression and therapy of lung cancer: the 19th Hiroshima Cancer Seminar: the 3rd Three Universities' Consortium International Symposium. Jpn J Clin Oncol, 40, 702-8.
  20. Takahashi E, Shiomi N, Shiomi T (1992). Precise localization of the excision repair gene, ERCC5, to human chromosome 13q32.3- q33.1 by direct R-banding fluorescence in situ hybridization. Jpn J Cancer Res, 83, 1117-9. https://doi.org/10.1111/j.1349-7006.1992.tb02731.x
  21. Walsh CS, Ogawa S, Karahashi H, et al (2008). ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol, 26, 2952-8. https://doi.org/10.1200/JCO.2007.13.5806
  22. Wood RD, Mitchell M, Sgouros J, et al (2001) Human DNA repair genes. Science, 291, 1284-9. https://doi.org/10.1126/science.1056154
  23. Zhang L, Gao G, Li X, et al (2012). Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. PLoS One, 7, e48350. https://doi.org/10.1371/journal.pone.0048350

Cited by

  1. Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: A meta-analysis based on 44 studies vol.2, pp.4, 2014, https://doi.org/10.3892/br.2014.282
  2. Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer vol.35, pp.6, 2014, https://doi.org/10.1007/s13277-014-1732-4
  3. Allele and Genotype Distributions of DNA Repair Gene Polymorphisms in South Indian Healthy Population vol.6, pp.1179-299X, 2014, https://doi.org/10.4137/BIC.S19681
  4. Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine vol.17, pp.12, 2016, https://doi.org/10.2217/pgs-2016-0074
  5. were associated with the overall survival of advanced non-small-cell lung cancer patients vol.5, pp.9, 2016, https://doi.org/10.1002/cam4.822
  6. Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems vol.34, pp.4, 2017, https://doi.org/10.1007/s12032-017-0905-6
  7. Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer vol.7, pp.1, 2017, https://doi.org/10.1038/s41598-017-08257-7
  8. Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis vol.7, pp.1, 2017, https://doi.org/10.1038/s41598-017-05642-0
  9. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies vol.79, pp.4, 2017, https://doi.org/10.1007/s00280-017-3280-2
  10. Association between the polymorphisms in XPG gene and gastric cancer susceptibility in Chinese populations vol.96, pp.42, 2017, https://doi.org/10.1097/MD.0000000000008213
  11. -regulation in normal bronchial epithelial cells vol.48, pp.7, 2016, https://doi.org/10.1152/physiolgenomics.00021.2016
  12. An insight into clinical outcome of XPG polymorphisms in breast cancer pp.1573-4978, 2018, https://doi.org/10.1007/s11033-018-4401-7